|
Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts Clinical research trials and Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts. Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts clinical trial. Test subjects typically receive the most expert healthcare available for their Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts  Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts
Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts
For Condition: Hypertrophic Cardiomyopathy,Left Ventricular Hypertrophy
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation. There is an inherited condition affecting the heart, passed on through genetics, hypertrophic cardiomyopathy (HCM). HCM causes the left ventricle to become abnormally enlarged (left ventricular hypertrophy LVH). Some patients with the abnormal genes that may cause HCM do not have the characteristic LVH. Approximately 20 - 40% of patients with the genetic abnormality (missense mutation of genes encoding for sarcomeric protein) actually have an enlarged left ventricle. Because of this, researchers believe there may be other factors, along with the genetic abnormality that contribute to the development of HCM. Researchers are interested in learning more about several factors they suspect may play a role in the development of HCM. Specifically, researchers plan to study levels of a hormone and the protein it attaches to, which may contribute to the development of an abnormally enlarged heart. Insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein (IGFBP) work together with growth hormone (GH) in the development and maturation of many organ systems. Previous studies have suggested that these hormones affect the development and function of the heart. Patients participating in this study will undergo a variety of tests including collection of blood samples, echocardiogram of the heart, treadmill exercise test, and continuous electrical monitoring of heart activity (Holter monitor).
Details: Hypertrophic cardiomyopathy (HCM) is a genetic disease with an autosomal dominant pattern of inheritance which is characterized by left ventricular hypertrophy (LVH). HCM is often caused by missense mutations of genes that encode for sarcomeric proteins. The LVH varies markedly in patients with identical sarcomeric gene mutations, and notably, 20 to 40% of subjects with disease mutation do not have LVH as assessed by echocardiography. These findings suggest that other factors affect LV wall thickness in HCM. We wish (1) to investigate the potential role of IGF-I and its binding protein, IGFBP3, in determining increased LV mass in HCM caused by sarcomeric mutations; and (2) to assess myocardial ultrasound backscatter, exercise tolerance, and propensity to arrhythmias, in subjects who have inherited sarcomeric mutations but who do not have LVH.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA HCM subjects 5 years or older, with distinct sarcomeric gene mutations and LV wall thickness greater than 15 mm in subjects older than 18 years, and greater than 2 SDs in subjects 18 years of age or younger, as assessed by MRI. Age- and gender-matched blood relatives with sarcomeric gene mutations but without LVH. Age- and gender-matched blood relatives without sarcomeric gene mutations. EXCLUSION CRITERIA History of hypertension (basal systolic and diastolic pressures above 170 mm Hg and 95 mm Hg, respectively) or another systemic or cardiac disease that may cause cardiac hypertrophy. History of recent acute illness or other chronic illness that might affect plasma levels of IGF-I and IGFBP3. History of thyrotoxicosis, diabetes mellitus or abnormally elevated fasting blood sugar. Any conditions which would exclude patients from undergoing MRI scan.
Total Enrollment: 175
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 990058; 99-H-0058
Study Start Date: February 26, 1999
Record last reviewed: August 28, 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001878
Other Left Ventricular Hypertrophy Studies:
1. Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
2. A Comparison of Two Treatments' Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
3. Study of Blood Flow in Heart Muscle
4. Evaluation of Patients with Known or Suspected Heart Disease
5. Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
Related Studies:
Other Left Ventricular Hypertrophy Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts
|
|
|
|
|
|
|
|
